GO:0070536 protein K63-linked deubiquitination: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070536 (protein K63-linked deubiquitination) describes the enzymatic removal of K63-linked polyubiquitin chains from substrate proteins, a reversible post-translational modification that controls signaling rather than proteasomal degradation.
• K63-linked deubiquitination is catalyzed by deubiquitinating enzymes (DUBs) including OTUD1, OTUD5, USP33, UCHL1, STAMBPL1 and BRISC-associated enzymes, which hydrolyze the isopeptide bond between ubiquitin Lys63 and the substrate.
• The process is central to innate immune and inflammatory signaling, where removal of K63 chains from TAK1, RIP2 or TRAF2 modulates NF-kB and cell-death outcomes.
• Dysregulated K63-linked deubiquitination contributes to diabetic kidney disease, sepsis-associated encephalopathy, cerebral ischemia, doxorubicin cardiomyopathy, arterial stiffness and multiple cancers.
• CRISPR knockout, point-mutation, knock-in and overexpression models are the primary tools for causally testing DUB-substrate relationships in this pathway.
• EDITGENE provides end-to-end CRISPR cell model and library screening services to dissect K63-linked deubiquitination in disease-relevant contexts.
Description
Protein K63-linked deubiquitination (GO:0070536) is the biological process in which a K63-linked ubiquitin chain, a polymer assembled through isopeptide bonds between lysine 63 of ubiquitin monomers, is enzymatically removed from a target protein. Unlike K48-linked chains that typically route substrates to the proteasome, K63-linked chains act as non-degradative scaffolds that recruit signaling complexes, so their removal by deubiquitinating enzymes (DUBs) is a decisive regulatory event. The reaction is catalyzed by DUBs such as OTUD1, OTUD5, USP33, UCHL1, STAMBPL1 and the BRISC complex, each with distinct substrate specificity. Because K63-linked deubiquitination controls the duration and amplitude of immune, inflammatory, metabolic and survival signals, it has emerged as a tractable target for understanding and manipulating human disease. This article integrates the QuickGO definition of GO:0070536 with verified primary literature to summarize its mechanism, key genes, disease links and the CRISPR-based methods used to study it.
protein K63-linked deubiquitination At A Glance
| GO ID | GO:0070536 |
|---|---|
| GO term | protein K63-linked deubiquitination |
| Ontology | biological_process |
| Synonym | none listed in QuickGO |
| Major function | Removal of K63-linked polyubiquitin chains from substrate proteins, reversing a non-degradative ubiquitin signal |
| Enzyme class | Deubiquitinating enzymes (DUBs), including OTU-domain, USP and JAMM/MPN enzymes |
| Key substrates | TAK1, RIP2, TRAF2, PRKN/parkin, Twist1, HK2, PPM1B, TOE1 |
| Pathway context | NF-kB signaling, mitophagy, TGF-beta signaling, inflammation, tumor metastasis |
What Is GO:0070536?
GO:0070536 is defined by QuickGO as a protein deubiquitination process in which a K63-linked ubiquitin chain, i.e. a polymer of ubiquitin formed by linkages between lysine residues at position 63 of the ubiquitin monomers, is removed from a protein. In practical terms, a DUB recognizes a substrate bearing a K63-linked polyubiquitin chain and cleaves the isopeptide bond, either trimming the chain or removing it entirely, thereby altering the substrate's interactome and signaling output.
Why Is protein K63-linked deubiquitination Important in Cell Biology?
K63-linked deubiquitination is important because it sets the threshold and duration of signals that would otherwise be constitutively active or prematurely terminated. By removing K63 chains from kinases and adaptors such as TAK1, RIP2 and TRAF2, DUBs directly shape inflammatory and cell-survival outputs, and their dysregulation is causally linked to metabolic, cardiovascular, neurological and malignant disease. Because the reaction is enzymatic and reversible, it is also highly druggable and genetically tractable, making GO:0070536 a focal point for both mechanistic research and therapeutic hypothesis testing.
• Controls non-degradative ubiquitin signaling, a layer distinct from proteasomal degradation.
• Regulates innate immune and inflammatory NF-kB signaling through TAK1, RIP2 and TRAF2.
• Modulates mitophagy by antagonizing PRKN/parkin-dependent ubiquitination.
• Promotes tumor metastasis via stabilization of Twist1 in non-small cell lung cancer.
• Drives hepatocellular carcinoma EGFR stability through a MYC-STAMBPL1-TOE1 axis.
• Contributes to diabetic kidney disease through podocyte OTUD5 activity.
• Exacerbates sepsis-associated encephalopathy via OTUD1-mediated HK2 release.
• Links to arterial stiffness through BRISC-mediated PPM1B deubiquitination.
• Provides a reversible node for therapeutic intervention in cardiovascular and metabolic disease.
• Enables CRISPR-based causal testing of DUB-substrate pairs in disease models.
What Happens During protein K63-linked deubiquitination?
Substrate recognition and DUB recruitment
In simple terms: The enzyme first finds and binds the protein carrying the K63 ubiquitin chain.
DUBs such as OTUD1, OTUD5, USP33, UCHL1 and STAMBPL1 are recruited to substrates through ubiquitin-binding domains and substrate-specific interfaces. For example, OTUD5 is recruited to TAK1 in podocytes, and USP33 engages PRKN/parkin to antagonize mitophagy. BRISC-associated activity targets PPM1B in arterial stiffness models.
Chain recognition and isopeptide bond cleavage
In simple terms: The enzyme cuts the chemical link that holds the K63 ubiquitin chain onto the target protein.
The catalytic domain of the DUB hydrolyzes the isopeptide bond between the C-terminus of the distal ubiquitin and Lys63 of the proximal ubiquitin or substrate, releasing free ubiquitin or shortened chains. This reverses the non-degradative signal and changes the substrate's binding partners.
Downstream signaling consequences
In simple terms: Once the chain is removed, the protein behaves differently and the signal changes.
Removal of K63 chains from RIP2 by OTUD1 inhibits inflammatory signaling in cerebral ischemia, whereas OTUD5-mediated deubiquitination of TAK1 reduces podocyte inflammation in diabetic kidney disease. In cancer, UCHL1 stabilizes Twist1 through K11/K63-linked deubiquitination to drive metastasis, and STAMBPL1 regulates TOE1 and EGFR stability in hepatocellular carcinoma.
Reversal and pathway feedback
In simple terms: The process can be turned back on by re-ubiquitination, creating a dynamic switch.
Because K63-linked deubiquitination is reversible, the same substrate can be re-ubiquitinated by E3 ligases, allowing cells to tune signaling duration. This balance is critical in mitophagy, where USP33 opposes PRKN/parkin activity, and in cardiomyopathy, where TRAF2 degradation alters mitochondrial function.
Key Genes Involved in GO:0070536 protein K63-linked deubiquitination
The following genes encode DUBs, substrates and adaptors experimentally linked to GO:0070536.
| Gene | Major Role | Research Relevance |
|---|---|---|
| OTUD1 | K63-linked DUB for RIP2 and HK2 | Inflammation, sepsis-associated encephalopathy, cerebral ischemia |
| OTUD5 | Deubiquitinates TAK1 | Diabetic kidney disease, podocyte inflammation |
| USP33 | Deubiquitinates PRKN/parkin | Mitophagy regulation |
| UCHL1 | K11/K63-linked DUB for Twist1 | Non-small cell lung cancer metastasis |
| STAMBPL1 | DUB in MYC-TOE1-EGFR axis | Hepatocellular carcinoma EGFR stability |
| BRISC complex | K63-linked DUB for PPM1B | High-fat/high-sucrose diet-induced arterial stiffness |
| TAK1 | Substrate kinase | Inflammatory signaling in kidney disease |
| RIP2 | Substrate adaptor | Cerebral ischemic injury |
| TRAF2 | Substrate adaptor | Doxorubicin cardiomyopathy |
| PRKN/parkin | Substrate E3 ligase | Mitophagy |
| Twist1 | Substrate transcription factor | Tumor metastasis |
| HK2 | Substrate metabolic enzyme | Microglia pyroptosis in sepsis |
| PPM1B | Substrate phosphatase | TGF-beta pathway activation |
| TOE1 | Substrate in EGFR axis | Hepatocellular carcinoma |
| MYC | Upstream regulator of STAMBPL1 | HCC feedback loop |
| EGFR | Downstream target | HCC stability |
How Is protein K63-linked deubiquitination Regulated?
K63-linked deubiquitination is regulated at multiple levels. DUB abundance and recruitment are controlled by upstream transcription factors such as MYC, which drives STAMBPL1 expression in hepatocellular carcinoma. Substrate availability and post-translational modifications of the DUB or substrate, such as phosphorylation, can alter catalytic activity and specificity. In addition, the balance between ubiquitination and deubiquitination is set by opposing E3 ligases, as seen for PRKN/parkin and USP33 in mitophagy, and for TRAF2 turnover in cardiomyopathy. Inflammatory and metabolic cues, including high-fat/high-sucrose diet and ischemic stress, further modulate pathway output.
protein K63-linked deubiquitination and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| OTUD5 | Diabetic kidney disease | Podocyte-specific knockout or knock-in mouse |
| OTUD1 | Sepsis-associated encephalopathy; cerebral ischemia | Microglia knockout and overexpression models |
| UCHL1 | Non-small cell lung cancer metastasis | Lung cancer cell lines with UCHL1 knockout |
| STAMBPL1 | Hepatocellular carcinoma | HCC xenografts with STAMBPL1 knockout |
| USP33 | Mitophagy dysregulation | USP33 knockout cells with PRKN/parkin readouts |
K63-linked deubiquitination in metabolic and kidney disease
OTUD5 in podocytes deubiquitinates TAK1 and reduces inflammation and injury in diabetic kidney disease. BRISC-mediated PPM1B-K63 deubiquitination activates the TGF-beta pathway and promotes high-fat/high-sucrose diet-induced arterial stiffness. These findings position GO:0070536 as a modifiable node in metabolic and renal pathology.
K63-linked deubiquitination in neurological injury and inflammation
OTUD1 disrupts K63-linked deubiquitination of RIP2 to ameliorate cerebral ischemic injury by inhibiting inflammation. In sepsis-associated encephalopathy, OTUD1 promotes HK2 mitochondrial release and microglia pyroptosis, exacerbating injury. Thus, the same process can be protective or detrimental depending on substrate and context.
K63-linked deubiquitination in cancer
UCHL1 stabilizes Twist1 via K11/K63-linked deubiquitination to drive metastasis in non-small cell lung cancer. A MYC-STAMBPL1-TOE1 positive feedback loop mediates EGFR stability in hepatocellular carcinoma. These studies link K63-linked deubiquitination to tumor progression and identify DUBs as candidate therapeutic targets.
K63-linked deubiquitination in cardiovascular injury
Proteasomal degradation of TRAF2 mediates mitochondrial dysfunction in doxorubicin cardiomyopathy, implicating ubiquitin-dependent signaling in cardiotoxicity. Together with arterial stiffness data, this supports a role for K63-linked deubiquitination in cardiovascular homeostasis.
From protein K63-linked deubiquitination-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is the DUB required for substrate deubiquitination? | CRISPR knockout cell line |
| Does a specific catalytic residue drive activity? | Point-mutation knock-in of catalytic cysteine |
| Does a disease-associated variant alter function? | Knock-in of patient variant |
| Where does the DUB act in cells? | Tagged knock-in with fluorescent or affinity tag |
| Does overexpression phenocopy disease? | Doxycycline-inducible overexpression |
| Which substrates depend on the DUB? | DUB knockout plus ubiquitin proteomics |
How to Study the protein K63-linked deubiquitination Process
| Method | What It Measures | Typical Application |
|---|---|---|
| K63 ubiquitin enrichment mass spectrometry | Abundance of K63-linked chains | Confirming DUB specificity |
| Co-immunoprecipitation | DUB-substrate interaction | Validating TAK1, RIP2, TRAF2 binding |
| NF-kB reporter assay | Inflammatory signaling output | Functional readout of deubiquitination |
| Mitophagy flux assay | Autophagic clearance | USP33-PRKN/parkin axis |
| Migration and invasion assay | Metastatic potential | UCHL1-Twist1 in lung cancer |
| Xenograft tumor growth | In vivo tumorigenicity | STAMBPL1 in HCC |
| Microglia pyroptosis assay | Cell death and inflammation | OTUD1 in sepsis |
| Arterial stiffness measurement | Vascular compliance | BRISC-PPM1B in metabolic stress |
Ubiquitin chain profiling by mass spectrometry
Mass spectrometry with K63-specific ubiquitin enrichment or diGly remnant profiling can quantify changes in K63-linked chains after DUB perturbation. This is the primary method to confirm that a candidate DUB acts on K63 linkages.
Co-immunoprecipitation and substrate validation
Co-immunoprecipitation of the DUB with candidate substrates such as TAK1, RIP2 or TRAF2, followed by ubiquitination assays, establishes substrate specificity. These experiments are typically performed in knockout versus wild-type cells.
Functional signaling assays
NF-kB reporter assays, cytokine secretion and cell-death measurements link K63-linked deubiquitination to downstream inflammatory and survival outputs. In cancer models, migration and invasion assays capture metastatic phenotypes.
In vivo disease models
Diet-induced arterial stiffness, diabetic kidney disease, cerebral ischemia and tumor xenograft models provide physiological context for DUB function. These models are essential for translating cell-based findings.
How CRISPR Can Be Used to Study GO:0070536 protein K63-linked deubiquitination
Knockout
CRISPR knockout of DUBs such as OTUD1, OTUD5, USP33, UCHL1 or STAMBPL1 removes the enzyme and reveals which substrates and pathways depend on K63-linked deubiquitination. Knockout cells are the standard starting point for substrate accumulation and signaling assays.
Point Mutation
Point mutation of the catalytic cysteine or other active-site residues abolishes deubiquitinase activity while preserving protein expression, allowing separation of catalytic from scaffold functions. This is critical for assigning causality to the enzymatic step of GO:0070536.
Knock-in
Knock-in of disease-associated variants or tagged alleles enables tracking of endogenous DUB localization and function. Tagged knock-in lines are particularly useful for imaging and interactome studies.
Overexpression
Overexpression of wild-type or mutant DUBs tests sufficiency and can phenocopy disease states such as metastasis or inflammation. Inducible overexpression systems provide temporal control.
How EDITGENE Supports protein K63-linked deubiquitination Research
Researchers studying protein K63-linked deubiquitination-related genes often need to determine whether a candidate gene is causally involved in substrate recognition, chain cleavage or downstream disease phenotypes. EDITGENE provides the CRISPR cell models and screening infrastructure required to move from correlation to causation in this pathway.
Contact EDITGENE today to design your custom CRISPR model for protein K63-linked deubiquitination research.
Frequently Asked Questions About protein K63-linked deubiquitination
What is protein K63-linked deubiquitination?
It is the enzymatic removal of K63-linked polyubiquitin chains from a protein, reversing a non-degradative ubiquitin signal.
What genes are involved in protein K63-linked deubiquitination?
Key genes include OTUD1, OTUD5, USP33, UCHL1, STAMBPL1 and BRISC complex components, along with substrates such as TAK1, RIP2, TRAF2 and PRKN/parkin.
What is the GO ID for protein K63-linked deubiquitination?
The GO ID is GO:0070536.
How does K63-linked deubiquitination differ from K48-linked deubiquitination?
K63-linked chains are non-degradative signaling scaffolds, whereas K48-linked chains typically target proteins for proteasomal degradation.
Which diseases are linked to K63-linked deubiquitination?
Diabetic kidney disease, sepsis-associated encephalopathy, cerebral ischemia, arterial stiffness, doxorubicin cardiomyopathy and several cancers.
What enzymes remove K63-linked ubiquitin chains?
Deubiquitinating enzymes including OTUD1, OTUD5, USP33, UCHL1, STAMBPL1 and BRISC-associated enzymes.
How can I study K63-linked deubiquitination with CRISPR?
Use knockout, point-mutation, knock-in or overexpression models to test DUB-substrate causality and downstream phenotypes.
What methods detect K63-linked deubiquitination?
K63 ubiquitin enrichment mass spectrometry, co-immunoprecipitation, NF-kB reporter assays and functional disease models.
Is K63-linked deubiquitination reversible?
Yes, substrates can be re-ubiquitinated by E3 ligases, making the process a dynamic switch.
Why is K63-linked deubiquitination important in cancer?
It stabilizes oncogenic proteins such as Twist1 and regulates EGFR stability in hepatocellular carcinoma.
Conclusion
GO:0070536 protein K63-linked deubiquitination is a central reversible modification that controls inflammatory, metabolic, cardiovascular and oncogenic signaling through DUBs such as OTUD1, OTUD5, USP33, UCHL1 and STAMBPL1. Its substrate specificity and disease relevance make it a high-value target for mechanistic and translational research. CRISPR-based knockout, point-mutation, knock-in and overexpression models, combined with ubiquitin proteomics and functional assays, provide the tools needed to dissect this pathway and identify therapeutic opportunities.
References
- 1. Liu Y et al.. 2025. BRISC-Mediated PPM1B-K63 Deubiquitination and Subsequent TGF-β Pathway Activation Promote High-Fat/High-Sucrose Diet-Induced Arterial Stiffness.. Circ Res 136(3):297-314 PMID: 39742393
- 2. Zhao Y et al.. 2024. Podocyte OTUD5 alleviates diabetic kidney disease through deubiquitinating TAK1 and reducing podocyte inflammation and injury.. Nat Commun 15(1):5441 PMID: 38937512
- 3. Jing G et al.. 2025. OTUD1 exacerbates sepsis-associated encephalopathy by promoting HK2 mitochondrial release to drive microglia pyroptosis.. J Neuroinflammation 22(1):154 PMID: 40500776
- 4. Niu K et al.. 2020. USP33 deubiquitinates PRKN/parkin and antagonizes its role in mitophagy.. Autophagy 16(4):724-734 PMID: 31432739
- 5. Feng Q et al.. 2025. UCHL1 stabilizes Twist1 via K11/K63-linked deubiquitination to drive tumor metastasis in non-small cell lung cancer.. Cell Death Discov 12(1):60 PMID: 41469388
- 6. Zhang H et al.. 2024. A MYC-STAMBPL1-TOE1 positive feedback loop mediates EGFR stability in hepatocellular carcinoma.. Cell Rep 43(10):114812 PMID: 39388352
- 7. Zheng S et al.. 2023. OTUD1 ameliorates cerebral ischemic injury through inhibiting inflammation by disrupting K63-linked deubiquitination of RIP2.. J Neuroinflammation 20(1):281 PMID: 38012669
- 8. Dhingra R et al.. 2022. Proteasomal Degradation of TRAF2 Mediates Mitochondrial Dysfunction in Doxorubicin-Cardiomyopathy.. Circulation 146(12):934-954 PMID: 35983756
